Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.

PURPOSE:Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS AN...

Full description

Bibliographic Details
Main Authors: Heather Spencer Feigelson, Chan Zeng, Pamala A Pawloski, Adedayo A Onitilo, C Sue Richards, Monique A Johnson, Tia L Kauffman, Jennifer Webster, Carsie Nyirenda, Gwen L Alexander, Clara Hwang, Deanna Cross, Catherine A McCarty, Robert L Davis, Denise Schwarzkopf, Andrew E Williams, Stacey Honda, Yihe Daida, Lawrence H Kushi, Thomas Delate, Katrina A B Goddard, CERGEN Study Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4006772?pdf=render

Internet

http://europepmc.org/articles/PMC4006772?pdf=render

Similar Items